Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bristol-Myers Squibb |
---|---|
Information provided by: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT00382460 |
The primary purpose of the study was to evaluate 4000 subjects with acute coronary syndrome by comparing pravastatin 40 mg to atorvastatin 80 mg to determine if they are clinically equivalent, and to evaluate the effectiveness of gatifloxacin therapy in reducing cardiovascular events in combination with statin therapy.
Condition | Intervention | Phase |
---|---|---|
Actue Coronary Syndromes |
Drug: PRAVASTATIN SODIUM |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Dose Comparison, Factorial Assignment, Efficacy Study |
Official Title: | Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22) |
Estimated Enrollment: | 4000 |
Study Start Date: | January 2001 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CV123-229, TIMI22 |
Study First Received: | September 27, 2006 |
Last Updated: | June 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00382460 |
Health Authority: | United States: Food and Drug Administration |
Pravastatin Atorvastatin |
Antimetabolites Pathologic Processes Disease Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents |
Syndrome Enzyme Inhibitors Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |